OncoSil Medical (ASX:OSL) said the German Institute for the Hospital Remuneration System authorized 120 German hospitals to negotiate fees for the OncoSil device classification under the NUB innovation funding program with statutory health insurance companies as part of annual budget negotiations, according to a Tuesday filing with the Australian bourse.
OncoSil received a "Positive Status 1" classification under the innovation funding program in 2021, the filing said.
In October 2024, the German Federal Joint Committee approved a directive for testing a new treatment method for pancreatic cancer, and in January, approval from the Ministry of Health was received, per the filing.
The Oncosil device is a targetted treatment directly to locally advanced pancreatic cancer delivered via injection and is used in combination with chemotherapy.
Shares surged 40% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。